Interferon‐free, direct‐acting antiviral therapy for chronic hepatitis C

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|22|11|861-870

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.22, Iss.11, 2015-11, pp. : 861-870

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interferon‐free, direct‐acting antiviral therapy for chronic hepatitis C

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 1352-0504, Iss. 11, 2015-11 ,pp. : 861-870

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systematic review with meta‐analysis: effectiveness and tolerability of interferon‐free direct‐acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 550-562

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon‐free direct‐acting antiviral combinations?

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 6, 2018-03 ,pp. : 848-849

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon‐free direct‐acting antiviral combinations? Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 6, 2018-03 ,pp. : 849-850

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 516-525

John Wiley & Sons Inc

Access to resources Recommend Favorite